Compare Cenovus Energy Inc (CVE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Novo Nordisk A/S — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Cenovus Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Novo Nordisk A/S for 116 Days on average.
| CVE | NVO | |
|---|---|---|
Market Cap | $57.90B | $165.31B |
Volume | 7,863,588 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $33.92 | $63.98 |
52-Week Low | $15.85 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $63.84B | $179.56B |
Dividend Yield | 1.97% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.39, up 2.48% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, ROE of 20.96%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight growing optimism around the company's growth prospects and attractive valuation metrics.
CVE presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors should monitor energy price volatility and execution risks. The company's improving cash flow outlook and shareholder returns through dividends provide additional support for long-term value creation.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
